SAM #HT9402-26-Q-9404

DHA Request for Quotes for Uniform Formulary Pharmaceutical Products

The Defense Health Agency is seeking pharmaceutical quotations for products under consideration for the Department of War Uniform Formulary. - Government buyer: Defense Health Agency (DHA), for the Department of War’s Military Health System. - Products requested: Adquey, Armlupeg, Beqalzi, Bixlenvo, Clotic, Etcamah, Langlara, Lisraya, Mimrylo, Nuzolvence, Rasonque, and Rezenopy. Therapeutic classes are described in the product line items below. - OEMs and vendors: No manufacturers, OEMs, or other vendors are named in the available notice. The product names are included as named pharmaceutical products, not identified manufacturers. - Procurement context: DHA is collecting quotes for products being considered for formulary placement. Depending on formulary decisions, DHA may establish Uniform Formulary Blanket Purchase Agreements or Uniform Formulary Additional Discount Program Agreements. - Notable requirements: Detailed pricing requirements are referenced in the RFQ and its price-list appendices. The available notice does not state product quantities or part numbers.

Description

The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ.

P&T COMMITTEE MEETING: The following November 2026 newly approved drugs will be reviewed:

a.  Adquey - Atopic - Subclass: Topical Agents b.  Armlupeg - White Blood Cell Stimulants - Subclass: Pegfilgrastims c.  Beqalzi - Oncological Agents - Non-BTKI for Chronic Lymphocytic Leukemia-Small Lymphocytic Lymphoma d.  Bixlenvo - Antiretrovirals - Subclass: Combinations e.  Clotic - Antifungals - Subclass: NA f.  Etcamah - Breast Cancer Agents - Estrogen Receptor Antagonist g.  Langlara - Insulins - Subclass: Basal h.  Lisraya - Targeted Immunomodulatory Biologics – NA i.  Mimrylo - Hematological Agents – NA j.  Nuzolvence - Antibiotics – NA k.  Rasonque - Oncological Agents - Subclass: RAS Inhibitors l.  Rezenopy - Alcohol Deterrants - Narcotic Antagonists

The RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9404.

Pre-quotation teleconference is on October 14, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2.

Additional Links:https://health.mil/PandT

View original listing